ESPR

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.35
Percentage change -11.51	%

Peers: AMGN REGN VRTX NBIX ALNY EXEL IONS PTCT MDGL NKTR

| Held by: IWM VTI VXF IWN VTWO IWO IWC ITOT BBP RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.66	Insider Own	1.00%	Shs Outstand	195.44M	Perf Week	-26.50%
Market Cap	530.03M	Forward P/E	8.11	EPS next Y	0.33	Insider Trans	-1.23%	Shs Float	195.06M	Perf Month	6.75%
Income	-86.77M	PEG	-	EPS next Q	-0.14	Inst Own	65.84%	Short Float	15.63%	Perf Quarter	53.71%
Sales	295.45M	P/S	1.79	EPS this Y	85.15%	Inst Trans	-5.03%	Short Ratio	6.64	Perf Half Y	-6.92%
Book/sh	-1.89	P/B	-	EPS next Y	210.03%	ROA	-32.41%	Short Interest	30.49M	Perf Year	90.78%
Cash/sh	0.73	P/C	3.66	EPS next 5Y	16.90%	ROE	-	52W Range	1.35 - 3.94	Perf YTD	-10.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.09%	ROI	-58.53%	52W High	-31.73%	Beta	0.99
Dividend TTM	-	Quick Ratio	1.37	Sales past 5Y	7.64%	Gross Margin	81.57%	52W Low	100.00%	ATR (14)	0.36
Dividend Ex-Date	-	Current Ratio	1.85	EPS Y/Y TTM	73.81%	Oper. Margin	10.00%	RSI (14)	48.98	Volatility	21.67% 11.88%
Employees	240	Debt/Eq	-	Sales Y/Y TTM	187.12%	Profit Margin	-29.37%	Recom	1.71	Target Price	7.51
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	58.91%	Payout	-	Rel Volume	4.16	Prev Close	3.04
Sales Surprise	0.63%	EPS Surprise	14.43%	Sales Q/Q	52.00%	Earnings	Nov 07 BMO	Avg Volume	4.59M	Price	2.69
SMA20	-2.68%	SMA50	13.90%	SMA200	20.00%	Trades		Volume	19,098,355	Change	-11.51%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-20-24	Downgrade	BofA Securities	Neutral → Underperform	$2.50
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy	$1.25 → $4
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform	$1
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform	$8 → $1.50
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral	$6.50 → $7
Feb-27-23	Resumed	BofA Securities	Neutral	$8
Feb-24-23	Upgrade	Jefferies	Hold → Buy	$12
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$9
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform	$7 → $6
May-05-22	Upgrade	JP Morgan	Underweight → Neutral	$6
Mar-10-22	Initiated	H.C. Wainwright	Buy	$22
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral	$28 → $11
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $11
May-05-21	Downgrade	Stifel	Buy → Hold	$37 → $20
Apr-26-21	Resumed	Credit Suisse	Outperform	$45
Mar-11-21	Initiated	Morgan Stanley	Equal-Weight	$30
Feb-12-21	Downgrade	Jefferies	Buy → Hold	$30

Show Previous Ratings

Dec-02-24 08:00AM	Esperion Announces New Drug Submissions in Canada for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk (GlobeNewswire) +10.71%
Nov-26-24 08:00AM	Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia (GlobeNewswire)
Nov-21-24 08:00AM	Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 10:30AM	Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 (GlobeNewswire)
Nov-08-24 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +8.06% +10.53%
02:08AM	Loading…
02:08AM	Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
Nov-07-24 07:10AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:08AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-04-24 08:00AM	Esperion to Participate in Upcoming Jefferies London Healthcare Conference (GlobeNewswire)
Oct-31-24 10:01AM	Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
08:00AM	Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions (GlobeNewswire)
Oct-24-24 08:00AM	Esperion to Report Third Quarter 2024 Financial Results on November 7 (GlobeNewswire)
Oct-17-24 07:02PM	Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings (GuruFocus.com)
Oct-03-24 04:56AM	Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? (Insider Monkey) +7.69%
08:00AM	Loading…
Oct-02-24 08:00AM	Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid (GlobeNewswire) +13.04%
Sep-25-24 04:30PM	Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-11-24 11:30AM	Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? (Zacks)
Sep-05-24 08:00AM	Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference (GlobeNewswire) -5.49%
Sep-03-24 08:00AM	Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) (GlobeNewswire)
Aug-26-24 08:00AM	Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 01:06AM	Q2 2024 Esperion Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-12-24 11:44AM	Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year (Zacks) -8.91%
07:10AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:09AM	Esperion Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-07-24 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-24 10:00AM	Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-25-24 08:00AM	Esperion to Report Second Quarter 2024 Financial Results on August 12 (GlobeNewswire)
Jul-24-24 08:00AM	Esperion to Participate in Upcoming BTIG Biotech Conference (GlobeNewswire)
08:00AM	Loading…
Jul-16-24 08:00AM	New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the Lipid Lurkers Inside Their Arteries (GlobeNewswire) +9.20%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
07:00AM	Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility (GlobeNewswire)
Jun-13-24 02:31PM	Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget (InvestorPlace)
Jun-11-24 10:00AM	3 Penny Stocks to Buy if You Want to Spend Less and Earn More (InvestorPlace)
Jun-06-24 11:31AM	Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report? (Zacks) +6.01%
May-23-24 12:11PM	Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk (Zacks) -5.46%
09:00AM	Esperion to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-22-24 08:00AM	First-In-Class Cholesterol-Lowering Treatment NILEMDO (NEXLETOL in the U.S.) and Its Combination with Ezetimibe, NUSTENDI (NEXLIZET in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk (GlobeNewswire)
May-20-24 10:30AM	Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise (MT Newswires) +5.08%
06:00AM	Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia (GlobeNewswire)
May-14-24 08:00AM	Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL and NEXLIZET (GlobeNewswire)
May-10-24 04:00PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-24 12:20PM	Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues (Zacks) -13.92%
11:08AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:04AM	Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ... (GuruFocus.com)
May-07-24 12:20PM	Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars (Benzinga) +11.79%
10:55AM	ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:55AM	Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase (GuruFocus.com)
08:22AM	Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today? (InvestorPlace)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:15AM	Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates (Zacks)
06:11AM	Esperion Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 08:00AM	Esperion to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-23-24 08:00AM	Esperion to Report First Quarter 2024 Financial Results on May 7 (GlobeNewswire) +9.42%
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Apr-07-24 02:45PM	Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity (GlobeNewswire)
Apr-01-24 08:00AM	Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 (GlobeNewswire)
Mar-28-24 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report? (Zacks)
Mar-26-24 08:00AM	Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-24 04:00PM	Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 (GlobeNewswire) +14.41%
Mar-22-24 06:26PM	U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use (Business Wire) +8.53%
03:10PM	U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use (GlobeNewswire)
11:04AM	CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events (GlobeNewswire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-28-24 08:34AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.38%
07:41AM	Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues (Zacks)
Feb-27-24 09:38PM	Q4 2023 Esperion Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.27%
07:53AM	Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023 (GuruFocus.com)
07:20AM	Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:25AM	Esperion Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-16-24 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-24 03:13AM	Should You Sell Esperion Therapeutics (ESPR)? (Insider Monkey)
Feb-13-24 10:00AM	Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27 (GlobeNewswire)
Feb-01-24 02:00PM	RFK, Esperion Therapeutics Announce 2024 Promotional Schedule (GlobeNewswire)
Jan-23-24 04:00PM	Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-19-24 08:50AM	Why Is Esperion Therapeutics (ESPR) Stock Down 24% Today? (InvestorPlace) -6.05%
Jan-18-24 09:15PM	Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock (GlobeNewswire) -16.34%
04:00PM	Esperion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-03-24 07:00AM	Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation (GlobeNewswire) -21.23%
Dec-18-23 08:00AM	Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +15.93%
Dec-13-23 04:00PM	U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet (GlobeNewswire) +14.57%
Dec-07-23 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report? (Zacks) +5.33%
Nov-13-23 10:30AM	Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023 (GlobeNewswire)
Nov-11-23 11:00AM	Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 (GlobeNewswire)
Nov-09-23 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -10.79%
Nov-08-23 01:16PM	Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues (Zacks)
11:04AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:19AM	Esperion Therapeutics Inc (ESPR) Reports 79% Y/Y Growth in Q3 Total Revenue (GuruFocus.com) +7.74%
07:15AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:06AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-01-23 10:01AM	Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-31-23 08:00AM	Esperion to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-24-23 08:00AM	Esperion to Report Third Quarter 2023 Financial Results on November 7 (GlobeNewswire)

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Warren Eric	Chief Commercial Officer	Nov 19 '24	Sale	2.17	197	427	162,355	Nov 20 04:10 PM
Warren Eric	Officer	Nov 19 '24	Proposed Sale	2.17	197	427		Nov 19 04:07 PM
Warren Eric	Chief Commercial Officer	Oct 17 '24	Sale	2.12	107	227	162,552	Oct 18 04:08 PM
Warren Eric	Officer	Oct 17 '24	Proposed Sale	2.12	107	227		Oct 17 03:25 PM
Koenig Sheldon L.	President and CEO	Sep 17 '24	Sale	1.80	14,550	26,132	752,266	Sep 18 04:12 PM
Warren Eric	Chief Commercial Officer	Sep 17 '24	Sale	1.78	2,608	4,650	162,659	Sep 18 04:11 PM
Foody Joanne M.	Officer	Sep 17 '24	Proposed Sale	1.78	3,381	6,015		Sep 17 04:02 PM
Warren Eric	Officer	Sep 17 '24	Proposed Sale	1.78	2,608	4,651		Sep 17 03:28 PM
Koenig Sheldon L.	Officer	Sep 17 '24	Proposed Sale	1.80	14,550	26,133		Sep 17 03:20 PM
Warren Eric	Chief Commercial Officer	Aug 19 '24	Sale	1.95	211	411	165,267	Aug 20 04:03 PM
Warren Eric	Officer	Aug 19 '24	Proposed Sale	1.95	211	410		Aug 19 03:50 PM
Warren Eric	Chief Commercial Officer	Jul 17 '24	Sale	2.59	108	279	165,478	Jul 19 08:30 AM
Foody Joanne M.	Chief Medical Officer	Jul 17 '24	Sale	2.60	917	2,383	272,862	Jul 19 08:29 AM
Foody Joanne M.	Chief Medical Officer	Jun 18 '24	Sale	2.87	3,285	9,418	273,779	Jun 20 04:20 PM
Warren Eric	Chief Commercial Officer	Jun 18 '24	Sale	2.86	2,540	7,254	165,586	Jun 20 04:16 PM
Warren Eric	Chief Commercial Officer	May 17 '24	Sale	2.48	192	477	168,126	May 20 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Esperion Therapeutics Inc

Upgrade your FINVIZ experience